60 Degrees Pharmaceuticals Inc
NASDAQ:SXTP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
60 Degrees Pharmaceuticals Inc
Cash from Financing Activities
60 Degrees Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
6
|
60 Degrees Pharmaceuticals Inc
NASDAQ:SXTP
|
Cash from Financing Activities
$7.1m
|
CAGR 3-Years
126%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$5.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
-$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
-11%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
-$10.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$1.9B
|
CAGR 3-Years
40%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
-$2.2B
|
CAGR 3-Years
26%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
60 Degrees Pharmaceuticals Inc
Glance View
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 2 full-time employees. The company went IPO on 2023-07-12. The firm is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Its lead product, ARAKODA (tafenoquine), is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. The firm's pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases; new products that contain the Arakoda regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. The ARAKODA regimen of tafenoquine is in Phase II study data in patients with mild-moderate COVID-19 disease. The company is also planning a clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. The firm is also developing Celgosivir for the treatment of COVID-19, respiratory syncytial virus (RSV), and dengue.
See Also
What is 60 Degrees Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
7.1m
USD
Based on the financial report for Dec 31, 2024, 60 Degrees Pharmaceuticals Inc's Cash from Financing Activities amounts to 7.1m USD.
What is 60 Degrees Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
126%
Over the last year, the Cash from Financing Activities growth was 9%. The average annual Cash from Financing Activities growth rates for 60 Degrees Pharmaceuticals Inc have been 126% over the past three years .
